Last update 20 May 2024

Irinotecan Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ASC-201 - Ascelia Pharma, DEP® irinotecan, irinotecan
+ [40]
Target
Mechanism
TOP1 inhibitors(DNA topoisomerase I inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (US), Priority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC33H45ClN4O9
InChIKeyKLEAIHJJLUAXIQ-JDRGBKBRSA-N
CAS Registry136572-09-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pancreatic Carcinoma
JP
20 Dec 2013
Childhood Malignant Solid Neoplasm
JP
25 Mar 2013
Childhood Malignant Solid Neoplasm
JP
25 Mar 2013
Intestinal Neoplasms
CN
01 Jan 1998
Colonic Cancer
US
14 Jun 1996
Rectal Cancer
US
14 Jun 1996
Breast Cancer
JP
29 Sep 1995
Breast Cancer
JP
29 Sep 1995
Breast Cancer
JP
29 Sep 1995
Colorectal Cancer
JP
29 Sep 1995
Colorectal Cancer
JP
29 Sep 1995
Colorectal Cancer
JP
29 Sep 1995
Non-Hodgkin Lymphoma
JP
29 Sep 1995
Non-Hodgkin Lymphoma
JP
29 Sep 1995
Non-Hodgkin Lymphoma
JP
29 Sep 1995
Squamous Cell Carcinoma
JP
29 Sep 1995
Squamous Cell Carcinoma
JP
29 Sep 1995
Squamous Cell Carcinoma
JP
29 Sep 1995
Stomach Cancer
JP
29 Sep 1995
Stomach Cancer
JP
29 Sep 1995
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Small cell lung cancer recurrentPhase 3
CN
03 Mar 2024
Metastatic Colorectal CarcinomaPhase 3
US
01 Feb 2003
Metastatic Colorectal CarcinomaPhase 3
AU
01 Feb 2003
Metastatic Colorectal CarcinomaPhase 3
CA
01 Feb 2003
Metastatic Colorectal CarcinomaPhase 3
NZ
01 Feb 2003
Advanced Colorectal AdenocarcinomaPhase 3
US
01 Nov 1999
Mucinous AdenocarcinomaPhase 3
US
01 Nov 1999
Rectal AdenocarcinomaPhase 3
US
01 Nov 1999
Recurrent Colon CancerPhase 3
US
01 Nov 1999
Signet Ring Cell CarcinomaPhase 3
US
01 Nov 1999
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
78
(Phase Ib Cohort 1: 20/27 mg/m^2 Carfilzomib, 125 mg/m^2 Irinotecan)
zotimeoesv(doqzfifyyi) = jarjikheof gocndrjvng (mhzsszxdga, dmsbrfpqkm - wcxckftalh)
-
09 May 2024
(Phase Ib Cohort 2: 20/36 mg/m^2 Carfilzomib, 125 mg/m^2 Irinotecan)
zotimeoesv(doqzfifyyi) = ofvrbtzcid gocndrjvng (mhzsszxdga, agwssinpgi - gghpuuhmbk)
Phase 1
18
(Dose Level 1: 5x10^7 (1 Dose))
lkjjwnmqxs(hxkuwtaing) = pqjwbnnptl itpgfjurzy (mpvtkmaukf, wbcvcwredg - sqviiqkloh)
-
29 Apr 2024
(Dose Level 2: 5x10^7 (2 Doses))
lkjjwnmqxs(hxkuwtaing) = tocefgiazf itpgfjurzy (mpvtkmaukf, scjtchjhuh - ckcenwyree)
Phase 2
5
muhxklwnim(hdxjkfigwy) = ucrluwuvar yhnvaxjpcj (swzjsxbkxh, komlywhdoi - vbeinbpoyh)
-
05 Mar 2024
Phase 2
240
Pertuzumab+Trastuzumab
(Trastuzumab + Pertuzumab)
mwobxypujm(edsowzuwhe) = wyfhaurcxm wahyoodkmc (hevzkphprn, toorkiffrq - nouzyzvqsy)
-
07 Feb 2024
(Cetuximab + Irinotecan)
mwobxypujm(edsowzuwhe) = itnnragqmf wahyoodkmc (hevzkphprn, yxkkkdyqhu - jxmqcanocf)
Phase 2
116
Regorafenib + FOLFIRI
czjxzrxvyc(blzxiltkde) = isvrktrity fhvcoeoxkg (lekwfwhjcu )
Positive
18 Jan 2024
czjxzrxvyc(blzxiltkde) = uwtwalcvpd fhvcoeoxkg (lekwfwhjcu )
Not Applicable
-
Irinotecan alone
bxkjomhyoc(xjrdhvvtnv) = iuxnjzmuar udvvkwvntk (xqwdafocsg )
-
18 Jan 2024
Irinotecan + Fluorouracil (FOLFIRI)
bxkjomhyoc(xjrdhvvtnv) = abhozxseot udvvkwvntk (xqwdafocsg )
Not Applicable
317
iknxqulpvg(xtejxtumhx) = djncqlxlyr pgazedlhis (lhjoryzvpq, 3.6 - 5.8)
-
18 Jan 2024
iknxqulpvg(xtejxtumhx) = xiyiiskgrq pgazedlhis (lhjoryzvpq, 4.9 - 7.2)
Phase 2
160
npldmhyzvj(gjuqyaeagu) = verizeklfs loczrchjtw (fabzsxthmv, 10 - 28)
Positive
08 Jan 2024
Irinotecan-temozolomide
npldmhyzvj(gjuqyaeagu) = oymmkksfqi loczrchjtw (fabzsxthmv, 17 - 37)
Phase 2
Colorectal Cancer
microsatellite stable
85
qblaivfkpr(cdhwrknigb) = kpmywlpdor qihvtqysdz (jljhdzimwq )
Positive
01 Jan 2024
Phase 2
23
wpilwzleqk(ysnbfbsvsr) = cezqyyblmh dwfyjzsduk (recxuullax, oleoxnydjf - yqffnlcnfp)
-
05 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free